Empowering public health services with Microsoft
In the face of a global pandemic and increasingly demanding patient needs, Microsoft’s David Rhew shares how technology can deliver virtual care experiences and accelerate the distribution of a vaccine for Covid-19
iStock
Between 2015 and 2050, the proportion of the world’s population over 60 years of age will nearly double from 12 per cent to 22 per cent, according to the World Health Organization.
“As we age, our ability to live independently, safely and confidently in our home diminishes,” says David Rhew, global chief medical officer and vice president of healthcare at Microsoft.
This change can occur gradually, over several years, due to progressive decline of physical and cognitive capabilities. Or it can be sudden and dramatic, such as after a stroke, heart attack or major fall. Either way, ageing in a safe and familiar location continues to be one of the most important goals for those affected and their careg
Patchwork of Rules Sows Confusion in State-by-State Vaccine Rollout
Bloomberg 1/12/2021 Michelle Cortez
(Bloomberg) An accelerating rush to give coronavirus vaccines to Americans is leading to confusion over who can get a shot when, and creating disparities that could complicate the push toward widespread immunity.
As Covid rips through the population and states struggle to vaccinate residents with limited supplies and a paucity of federal assistance, some governors are opting for radical solutions. Rather than giving initial vaccines only to the elderly and front-line health workers, they’re offering shots to a wide swath of people to quickly reach the maximum possible.
10:00 – 11:00 am
2020 was a year like no other as the annual biopharma M&A total fell to the lowest level since EY began publishing its annual M&A Firepower report in 2013. In the first half of the year, the specter of COVID-19 deterred deals; as economies started to reopen, persistently high valuations were another reason many buyers remained on the fence. In the midst of such uncertainty, an innovation narrative emerged, with growing evidence of the power of new technologies, from antibody drug conjugates in oncology to RNA-based vaccines. These new innovations sparked many of 2020’s most notable deals and are sure to be important in the future. In this one hour panel discussion, we will discuss the current state of biopharma dealmaking and its implications for 2021 with M&A leaders from across the industry.
Happy holidays from all of us at The Record!
The team at
The Record would like to wish all of our readers a happy and peaceful holiday period, and all the best for 2021.
Over the past 12 months, we’ve brought you a wide range of news about the latest technology and insights from Microsoft and its enterprise partner network, and we hope you’ve enjoyed reading it as much as we have compiling it.
If you have a bit of free time over the festive period, why not take a look at some of our highlights from 2020?
Over the past year, we have spoken with Microsoft executives including general manager of worldwide communications and media Bob De Haven, worldwide general manager of automotive Sanjay Ravi, corporate vice president of Microsoft’s One Commercial Partner organisation Gavriella Schuster, and Microsoft’s global industry general manager Çağlayan Arkan. And in the Winter 2020 issue, we’ll get more insights from healthcare lead David Rhew as discusses a Covid